Should Aspirin Be the Second-Line Antiplatelet in CAD? Should Aspirin Be the Second-Line Antiplatelet in CAD?

From European Society of Cardiology 2022, Drs O ' Donoghue and Valgimigli discuss the latest analysis suggesting that for single antiplatelet therapy in patients with CAD, P2Y12 inhibitors beat aspirin.theheart.org on Medscape

Source: Medscape Cardiology Headlines - August 31, 2022 Category: Cardiology Tags: Cardiology Commentary Source Type: news